Looking Ahead to Change: Little by Little
I don't make New Year's Resolutions. I don't think I ever really did, but the last decade or two would have been enough to stifle that impulse. I've just been too aware that I don't have that much control over what happens in my life.
Discuss the article on the Forums.

Status of Rituximab-ME/CFS Studies

Discussion in 'Rituximab: News and Research' started by Persimmon, Feb 15, 2012.

  1. lansbergen

    lansbergen Senior Member

    Messages:
    2,118
    Likes:
    1,745
    .
    My guess: If new Tcells are spared from this they might work properly but it will take time to get enouigh healthy Tcells.
     
  2. liquid sky

    liquid sky Senior Member

    Messages:
    371
    Likes:
    211
    "Ocrelizumab has previously been investigated as a treatment for rheumatoid arthritis but studies were discontinued because of a high incidence of opportunistic infections in participants. Opportunistic infections are infections that do not normally occur in a healthy person but may occur when the immune system is compromised."

    This new B cell depletion drug, Ocrelizumab, has not been safer than Rituxan. Rituxan has been approved for years in RA with a good safety profile. http://www.medpagetoday.com/MeetingCoverage/ACR/35895
     

See more popular forum discussions.

Share This Page